ASH 2017 | Novel ALL treatment strategies: CAR T-cells
Elias Jabbour
CAR T-cells are a universally exciting area in hematological oncology. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Elias Jabbour, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the landscape of CAR T-cell therapy for acute lymphoblastic leukemia (ALL). He covers the approval of the CAR T-cell product tisagenlecleucel for pediatric and adolescent ALL based on data from the Phase II ELIANA trial (NCT02435849). Dr Jabbour also discusses the landscape of this field moving forwards, including the potentially game-changing use of off-the-shelf allogeneic CAR T-cell therapy.
Similar topics
Related videos

Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill

An exciting era for CAR T-cell therapy
Mohamad Mohty

Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno

JCAR017 for relapsed/refractory CLL
Tanya Siddiqi

Combining novel agents for CLL to achieve deep remissions: time-limited therapy, treatment cessation & drug re-use in relapse
Talha Munir
10th December 2017
More from Elias Jabbour